OBOT: Office-Based Opioid Treatment
OBOT is buprenorphine-based medication-assisted treatment for opioid use disorder delivered in office-based settings — primary care, community mental health, or specialty addiction medicine. Distinct from OTPs, which dispense methadone in federally regulated programs.
How OBOT works
Patients are evaluated for opioid use disorder, started on buprenorphine (often in the office for the first dose), and followed at intervals appropriate to clinical stability. Counseling and behavioral therapy are integrated either in-house or via referral. Care management is increasingly central — telehealth-based OBOT programs have meaningfully expanded access since 2020.
Post-X-Waiver landscape (2023+)
The MAT Act of 2022 eliminated the buprenorphine X-Waiver effective January 2023. Any DEA-registered clinician can now prescribe buprenorphine without separate certification. The bottleneck has shifted from regulatory to clinical workforce comfort and care management capacity.
OBOT analytics priorities
- Treatment retention at 6 and 12 months — the strongest single outcome predictor.
- Same-day or next-day buprenorphine initiation for patients presenting in withdrawal.
- Co-occurring BH screening compliance for OBOT patients (PHQ-9, GAD-7, PCL-5).
- SDOH stratification — housing, employment, transportation barriers strongly predict retention.
Where Vizier fits
Vizier reads OBOT prescribing data, BH encounter data, and SDOH screening data from the EHR connector. Provider-level dashboards surface buprenorphine prescriber utilization, patient retention curves, and outreach worklists for patients at risk of disengagement.